BioSpace News Archive

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020. About Personalis, Inc. Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more compr

Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, today announced the naming of Kerem Bolukbasi as its new Chief Financial Officer (CFO). Bolukbasi joins Exactech from TPG Capital where he served as an Operations Executive and was responsible for pro

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020

Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020 Strategic co-promotion partnership with Menarini Silicon Biosystems to market and sell Menarini’s COVID-19 related products Conference call to be held at 4:30 p.m. Eastern Time today GAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular di

Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today reported financial results and provided program highlights for the second quarter ended June 30, 2020. “Viela had another productive quarter marked by the U.S. FDA approval of UPLIZNA™ —also known as inebilizumab—in the U.S.,” said Bing Yao, Ph.D., Chief Ex

Recursion and University of Utah found incubator to propel new generation of life sciences in the region

BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on August 3, 2020, the compensation committee of BridgeBio’s board of directors granted twenty-two employees options to purchase an aggregate of 30,443 shares of the Company’s common stock with a per share exercise price of $27.20 and restricted stock units for an aggregate of 61,760 shares of the Company’s common stock.

Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced that the company will present at Oppenheimer’s Private Life Sciences Company Call Series, held virtually August 17-19, 2020

In a release issued earlier today under the same headline by Vaxcyte, Inc. (Nasdaq: PCVX), please note that in the first bullet under “Recent Highlights”, the date should be June 16, 2020, not June 16, 2010. The corrected release follows: Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most commo

Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020. The Company’s revenue for the quarter ended June 30, 2020 was $3.3 million versus $9.3 million for the quarter ended June 30, 2019, a decrease of 64%. Net loss for the quarter ended June 30, 2020 was $2.1 million or ($0.37) per diluted share, versus net income of $0.8 million or $0.14 per diluted share, for the comparable